Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Carbone

Showing results (241-250 of 283) with videos related to

Pageof 29
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 3, 2007
Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancerPinar B Yildiz, Yu Shyr, Jamshedur S M Rahman, et al.
Investigational New Drugs|December 3, 2025
Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancerDwight H Owen, Ruohan Wu, Lai Wei, et al.
Oncogene|August 5, 2018
RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patientsAnna Tessari, Kareesma Parbhoo, Meghan Pawlikowski, et al.
Clinical Lung Cancer|February 8, 2022
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not ChemoimmunotherapyYizhen Guo, Lai Wei, Sandip H Patel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomesMartin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Journal for Immunotherapy of Cancer|February 6, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer typesDavid R Gandara, Neeraj Agarwal, Shilpa Gupta, et al.
Journal for Immunotherapy of Cancer|February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trialDavid P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Cancer Discovery|June 18, 2025
Tumor-associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint BlockersNo-Joon Song, Juan Xie, Kyeong Joo Jung, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 8, 2025
The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging DatabaseDavid P Carbone, Fred R Hirsch, Raymond Uyiosa Osarogiagbon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 28, 2016
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016Daniel S W Tan, Sue S Yom, Ming S Tsao, et al.
Pageof 29

Showing results (241-250 of 283) with videos related to

Sort By:
Pageof 29
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 3, 2007
Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancerPinar B Yildiz, Yu Shyr, Jamshedur S M Rahman, et al.
Investigational New Drugs|December 3, 2025
Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancerDwight H Owen, Ruohan Wu, Lai Wei, et al.
Oncogene|August 5, 2018
RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patientsAnna Tessari, Kareesma Parbhoo, Meghan Pawlikowski, et al.
Clinical Lung Cancer|February 8, 2022
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not ChemoimmunotherapyYizhen Guo, Lai Wei, Sandip H Patel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomesMartin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Journal for Immunotherapy of Cancer|February 6, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer typesDavid R Gandara, Neeraj Agarwal, Shilpa Gupta, et al.
Journal for Immunotherapy of Cancer|February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trialDavid P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Cancer Discovery|June 18, 2025
Tumor-associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint BlockersNo-Joon Song, Juan Xie, Kyeong Joo Jung, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 8, 2025
The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging DatabaseDavid P Carbone, Fred R Hirsch, Raymond Uyiosa Osarogiagbon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 28, 2016
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016Daniel S W Tan, Sue S Yom, Ming S Tsao, et al.
Pageof 29